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Abstract
Summary This study compares efficacy of ALN/D5600 ver-
sus that of calcitriol in osteoporotic Chinese postmenopausal
women. ALN/D5600 produced greater bone mineral density
(BMD) increases, greater bone turnover marker decreases,
and less vitamin D insufficiency. This study provided detailed
clinical information regarding ALN/D5600 treatment versus
calcitriol 0.25 μg/day. The study did not evaluate fracture risk.
Introduction The aim of this study is to investigate efficacy of
alendronate 70 mg/vitamin D3 5600 IU combination tablets
(ALN/D5600) versus calcitriol in osteoporotic Chinese post-
menopausal women.
Methods This study is a 6-month, randomized, open-label,
act ive-comparator study with 6-month extension
(clinicaltrials.gov number NCT01350934) in postmenopausal
women aged >55 years with osteoporosis (low bone mineral
density (BMD) with/without prior fragility fracture). Patients
were randomized to ALN/D5600 once weekly or calcitriol
0.25μg daily. The primary efficacy end point of the base study
was percent change from baseline in lumbar spine BMD
(month 6). Hypercalcemia and hypercalciuria were safety
events of special interest.
Results A total of 219 patients (ALN/D5600 n=111,
calcitriol n=108) were randomized. Baseline characteristics
were similar, 30.3 % baseline 25-hydroxyvitamin D
(25(OH)D) ≤15 ng/mL. At months 6 and 12, changes in lum-
bar spine BMD from baseline were 3.5 versus 1.6 % and 5.2
versus 2.3 % for ALN/D5600 versus calcitriol (between-
group differences p<0.001), respectively. Between-group dif-
ferences for ALN/D5600 versus calcitriol were significant
(p<0.001) at months 6 and 12 for change from baseline in
procollagen type 1 N-terminal propeptide (−59.1 versus
−16.8 %, −68.1 versus −17.0 %) and serum C-telopeptides
(−79.2 versus −27.2 %, −76.2 versus −24.2 %). Drug-related
adverse events (AEs) and discontinuations due to drug-related
AEs occurred in 15 (14.0 %) versus 8 (7.4 %) patients and 3
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(2.8 %) versus 0 patients in the ALN/D5600 and calcitriol
group, respectively. Hypercalciuria 12-month incidence
(24-h urine Ca >300 mg) was 8.4 (ALN/D5600) versus
13.9 % (calcitriol) (p>0.05). One patient (calcitriol) had
hypercalcemia.
Conclusions ALN/D5600 produced greater increases in lum-
bar spine BMD and greater decreases in bone turnover
markers versus calcitriol in osteoporotic Chinese women. It
is not known whether the greater increase in BMD results in
fewer fractures. ALN/D5600 was generally well tolerated in
Chinese patients.
Keywords Alendronate .Calcitriol .China . Postmenopausal
osteoporosis . VitaminD
Introduction
Osteoporosis is an important public health problem in China,
with increased life expectancy and lifestyle changes set to
contribute to increased incidence in the future [1]. In 2010,
according to the National Bureau of Statistics of China, >169
million (26.0 %) Chinese women were aged over 50 years [2].
The prevalence of osteoporosis in Chinese women aged over
50 years has been estimated at 40.1 % [3]. Prevention and
treatment of osteoporosis include ensuring that patients re-
ceive adequate calcium and vitamin D [4]. Relatively few
types of food contain significant amounts of vitamin D, and
as a result, supplements are generally used to treat and prevent
vitamin D insufficiency. It has been found that vitamin D
insufficiency is a common but largely ignored health problem
in China [5, 6], with insufficiency (defined in this case as 25-
hydroxyvitamin D (25(OH)D) <20 ng/mL) found in as many
as 70–90 % of elderly people in Beijing and Shanghai [6]. A
recent large, cross-sectional study conducted in individuals
living in northwest China found that the prevalence of
25(OH)D levels <20 ng/mL in the general population
of women aged 40–75 years was 80 %, although reduced
vitamin D levels were not associated with an increased risk
of osteoporosis [7].
The bisphosphonate alendronate has been approved for the
treatment of osteoporosis in postmenopausal women at a dose
of 10 mg daily or 70 mg once weekly. Alendronate has been
shown to increase bone mineral density (BMD) and reduce
bone turnover in postmenopausal Chinese women with oste-
oporosis [8]. A combined formulation of alendronate 70 mg/
vitamin D3 5600 IU (ALN/D5600), developed to ensure that
osteoporotic patients taking alendronate also receive adequate
vitamin D, has also been approved in China.
In this study, the efficacy and safety of ALN/D5600 versus
those of calcitriol (1,25(OH)2D3) were compared in Chinese
postmenopausal women. Calcitriol, the active hormonal me-
tabolite of vitamin D3, is also currently approved and
commonly prescribed for postmenopausal osteoporosis in
China. The originally approved dose of calcitriol for postmen-
opausal osteoporosis was 0.25μg twice daily; however, due to
safety concerns, calcitriol 0.25 μg daily has become the most
commonly prescribed regimen in local practice.
We hypothesized that ALN/D5600 administered once
weekly as a combination tablet would increase lumbar spine
BMD more than calcitriol 0.25 μg daily after both 6 and
12 months treatment. Administration of high doses of either
vitamin D3 or calcitriol may produce hypercalcemia and/or
hypercalciuria, so both urine and serum calcium levels were
monitored as safety end points.
Methods
Study design
This was a 6-month, randomized, open-label, active-compar-
ator-controlled, parallel-group study with a 6-month extension
to evaluate the efficacy and safety of ALN/D5600 once week-
ly as a combination tablet versus those of calcitriol 0.25 μg
daily in the treatment of osteoporosis in postmenopausal
women in China (protocol number 264–01, clinicaltrials.gov
number NCT01350934). After screening, patients were ran-
domized to ALN/D5600 or calcitriol for 6 months in the base
study, and for a further 6 months in the extension study. Cal-
cium supplements (500 mg daily) were administered to all
patients for the entire 12 months. Study medications were as
follows: Fosamax® Plus D (alendronate 70 mg/vitamin D3
5600 IU; manufactured by FROSST IBERICA. SA, a subsid-
iary of Merck, packaged by MSD, Australia); and Rocaltrol®
(calcitriol 0.25 μg; manufactured by R.P. Scherer GmbH &
Co. KG under Hoffman-La Roche AG, packaged by Roche,
Shanghai, China).
The primary efficacy end point of the base study was per-
cent change from baseline in lumbar spine BMD at month 6.
The secondary efficacy end point of the base study was per-
cent change from baseline in the biochemical markers of bone
turnover procollagen type 1 N-terminal propeptide (P1NP)
and serum C-telopeptides of type 1 collagen (s-CTx) at month
6. Exploratory end points of the base study were at month 6:
percent change from baseline in total hip, femoral neck, and
trochanter BMD; the proportion of patients with serum
25(OH)D <20 ng/mL; the proportion of patients with serum
25(OH)D <15 ng/mL; the change from baseline in mean se-
rum 25(OH)D level. The safety and tolerability of ALN/
D5600 once weekly in this population were also investigated
throughout the study.
Efficacy end points of the extension study were at month
12: percent change from baseline in lumbar spine BMD; per-
cent change from baseline in total hip, femoral neck, and tro-
chanter BMD; percent change from baseline in the
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biochemical markers of bone turnover P1NP and s-CTx; the
proportion of patients with serum 25(OH)D <20 ng/mL; the
proportion of patients with serum 25(OH)D <15 ng/mL; the
change from baseline in mean serum 25(OH)D level.
The study was approved by the independent ethics com-
mittees of 13 participating sites.Written informed consent was
obtained in accordance with the principles and provisions of
the International Conference on Harmonization-E6 Guideline
for Good Clinical Practice (GCP) following country-specific
consent requirements.
The study was sponsored by MSD China Holding Co.,
Ltd., China, and jointly administered with PAREXEL China.
Patients
Eligible patients were >55 years of age and postmenopausal
for at least 1 year (womenwho were not postmenopausal were
not eligible for inclusion). The patients were also required to
have the following: either BMD T-score≤-2.5 in at least one
anatomic site (lumbar spine, total hip, or femoral neck) or
prior non-pathological fragility fracture (of the spine, wrist,
humerus, or clavicle) and BMD T-score≤-1.5 in at least one
of the same anatomic sites; 25(OH)D levels ≥8 ng/mL
(20 nmol/L); no prior hip fracture; no abnormal finding of
clinical significance (no pronounced medical history other
than osteoporosis, including as follows: history of malignancy
<5 years prior to signing study consent, with melanoma, leu-
kemia, lymphoma, or myeloproliferative disorders of any du-
ration leading to exclusion; uncontrolled primary/secondary
hyperparathyroidism; malabsorption syndrome; history or ev-
idence of metabolic bone disease other than osteoporosis or
abnormal serum calcium or phosphate); no treatment with
specific drugs for specified time periods (including past oral
bisphosphonate or recombinant parathyroid hormone); and no
contraindications to alendronate, calcitriol, or vitamin D.
Efficacy assessments
BMD was assessed at screening, month 6 and month 12 via
dual-energy X-ray absorptiometry (DXA), using a Hologic
(Hologic Corporation) or GE Lunar (GE Medical Systems)
densitometer at study sites. The percent change from baseline
in lumbar spine, total hip, femoral neck, and trochanter BMD
was calculated. Lateral spine X-ray of T4-L5 (one thoracic
and one lumbar X-ray) was performed at screening, month 6
and month 12. Biochemical markers of bone turnover, P1NP,
and s-CTx were measured at day 1, month 6, and
month 12 using P1NP immunoassay and s-CTx
electrochemiluminescent immunoassay (Roche Cobas E601
platform using Roche reagents), and assessed at a central lab-
oratory (Quest Diagnostics, Shanghai, China). A constrained
longitudinal data analysis (cLDA) method was used to ana-
lyze these biochemical markers.
Serum 25(OH)D levels were assessed using liquid
chromatography-tandem mass spectrometry (LCMSMS;
API4000 platform) at a central laboratory (Quest Diagnostics,
Shanghai, China) and monitored throughout the study. The
total of both 25(OH)D3 and 25(OH)D2 was reported as
25(OH)D.
Safety assessments
Safety was assessed using reported adverse events (AEs) and
laboratory safety evaluations (including the following: blood
chemistry and urinalysis, with but not limited to, evaluation of
albumin, blood urea nitrogen, and creatinine; serum calcium;
and 24-h urine calcium), physical examinations, measurement
of vital signs, and 12-lead electrocardiogram (ECG). Hyper-
calcemia (defined as total serum calcium (not corrected for
protein) >2.60 mmol/L) and hypercalciuria (defined as 24-h
urine calcium excretion >300 mg) were safety events of spe-
cial interest. Serum calcium was assessed at screening, ran-
domization, and at 3, 6, 9, and 12 months, and 24-h urinary
calcium was assessed at randomization and at 6 and
12 months.
Statistical analyses
The base study planned to enroll 100 patients per group in a
1:1 ratio to receive ALN/D5600 or calcitriol. The study had
approximately 97 % power (2-sided, α=0.05) to demonstrate
the primary hypothesis that treatment with ALN/D5600 was
superior to treatment with calcitriol as measured by percent
change from baseline in lumbar spine BMD at month 6. This
was based on the following assumptions: (a) an underlying
2 % treatment difference between ALN/D5600 IU and
calcitriol, (b) a standard deviation (SD) of 3.3 % for percent
change from baseline in lumbar spine BMD at month 6, and
(c) approximately 15 % of the patients would discontinue
prior to month 6 (for any reason). The extension study had
more than 99 % power (2-sided, α=0.05) to demonstrate that
treatment with ALN/D5600 IU was superior to treatment with
calcitriol as measured by percent change from baseline in the
lumbar spine BMD at month 12 based on the following as-
sumptions: (a) an underlying 4 % treatment difference be-
tween ALN/D5600 IU and calcitriol, (b) an SD of 3.3 % for
percent change from baseline in lumbar spine BMD at month
12, and (c) a further 5 % of patients would discontinue prior to
month 12.
Efficacy analyses were performed on the full analysis set
(FAS) comprising all randomized patients whowere subject to
≥1 dose of study treatment and ≥1 post-randomization obser-
vation for analysis end point subsequent to ≥1 dose of study
treatment, and the per-protocol set (PPS), which excluded pa-
tients due to major protocol deviations. The primary analysis
population was the FAS for assessment of changes in BMD
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and the PPS for bone turnover indices. A longitudinal data
analysis method was used to determine percent changes from
baseline in each of the efficacy end points, with adjustments
for treatment, time, interactions of time by treatment, and
baseline covariates such as 25(OH)D level stratum (≤15 ver-
sus >15 ng/mL). For biochemical markers of bone turnover,
P1NP and s-CTx, percent change from baseline in log scale
was the analytic metrics. The estimates of the between- and
within-group treatment means and the associated 95 %
confidence intervals (CIs) were back-transformed for
presentation.
Safety data were analyzed in the all patients as treated
(APaT) population (all randomized patients who received ≥1
dose of study treatment). The analysis of safety results follow-
ed a tiered approach. The proportion of patients who devel-
oped either hypercalcemia or hypercalciuria was identified a
priori as an AE of special interest and was considered a tier 1
event. AEs and predefined limits of change in laboratory
values, vital signs, and ECG parameters were classified as tier
2 or tier 3 events based on the number of events observed. P
values (tier 1 only) and 95 % CIs (tier 1 and tier 2) for
between-treatment differences in the percent of patients with




From July 2011 through January 2013, 304 patients were
screened from 13 centers in China, of whom 219 (72.0 %)
were randomized to receive either ALN/D5600 (n=111) or
calcitriol (n=108) (Fig. 1). Four patients (1.8 %) from the
ALN/D5600 group were randomized but did not receive the
study drug. A total of 196 (89.5 %) patients completed the
study, and 23 (10.5 %) patients discontinued from the study.
The most common reason for early discontinuation was
an AE, which was reported in 8 (7.2 %) patients from
the ALN/D5600 group and 1 (0.9 %) patient from the
calcitriol group.
Demographic and baseline characteristics were comparable
between treatment groups (Table 1). Overall, the mean age
was 65 years and all patients were Asian, except two in the
calcitriol group who were Caucasian. Mean 25(OH)D levels
were 19.8 and 19.4 ng/mL in the ALN/D5600 and calcitriol
groups, respectively, and the percentages of patients with
25(OH)D values of ≤15 and >15 ng/mL were similar in both
treatment groups. Of note, 63/208 (30.3 %) patients had a
25(OH)D level of ≤15 ng/mL. Use of either calcium carbonate
plus cholecalciferol or other unspecified vitamin D forms was
reported by 4.3 and 3.8 % of patients, respectively.
Efficacy
Lumbar spine, total hip, femoral neck, and trochanter BMD
Percent changes from baseline (least squares (LS) mean) of
the lumbar spine BMD at month 6 (primary efficacy end
point) in the FAS were 3.5 % (95 % CI 2.7, 4.4; standard error
(SE), 0.42) and 1.6 % (95 % CI 0.8, 2.4; SE 0.41) for ALN/
D5600 and calcitriol, respectively; there was a between-
treatment difference of 2.0 % (95 % CI 0.8, 3.1; p<0.001
adjusted for 25(OH)D level stratum as a baseline covariate)
(Fig. 2a). At month 12, the percent changes (LS mean) of
lumbar spine BMD were 5.2 % (95 % CI 4.3, 6.0) and
2.3 % (95 % CI 1.4, 3.1) for the ALN/D5600 and calcitriol
groups, respectively,; there was a between-treatment differ-
ence of 2.9 % (95 % CI 1.8, 4.1; p<0.001 adjusted for
25(OH)D level stratum as a baseline covariate). Analysis in
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Non-compliance with study drug=0
Extension study
Fig. 1 Patient disposition.ALN/D5600 combination tablet of alendronate
70 mg plus vitamin D3 5600 IU once weekly
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lumbar spine BMD at months 6 and 12, supporting the prima-
ry analysis result.
Within-treatment differences in BMD percent changes
from baseline (LS mean) of the total hip, femoral neck, and
trochanter at month 6 for ALN/D5600 were 1.6 % (95 % CI
0.9, 2.4), 2.8 % (95 % CI 1.2, 4.3), and 2.2 % (95 % CI 0.9,
3.5), and for calcitriol were 0.5 % (95 % CI −0.2, 1.2), 0.8 %
(95 % CI −0.7, 2.2), and 0.4 % (95 % CI −0.8, 1.7), respec-
tively (Fig. 2b–d). Corresponding data at month 12 for ALN/
D5600 were 2.7 % (95 % CI 1.7, 3.6), 3.3 % (95 % CI 1.9,
4.7), and 2.4 % (95 % CI 0.9, 3.8), and for calcitriol were
0.1 % (95 % CI −0.8, 1.0), 0.4 % (95 % CI −0.9, 1.8), and
0.1 % (95 % CI −1.3, 1.5), respectively. Between-treatment
differences were statistically significant for the total hip and
trochanter at month 6, and for the total hip, femoral neck, and
trochanter at month 12.
Bone turnover biomarkers
At months 6 and 12, percent changes from baseline in P1NP
(Fig. 3a) and s-CTx (Fig. 3b) (determined for the PPS) showed
significantly greater decreases with ALN/D5600 than with
calcitriol.
Within-treatment differences in percent changes from base-
line (LS mean) of P1NP and s-CTx at month 6 for ALN/
D5600 were −59.1 % (95 % CI −62.0, −56.0) and −79.2 %
Table 1 Summary of demographics and other baseline characteristics
by treatment group (FAS)




Age (years) 65.6 (8.0) 64.8 (7.4)
Height (cm) 155 (5.5) 155 (6.4)
Weight (kg) 55.1 (8.3) 54.6 (8.2)
BMI (kg/m2) 23.0 (3.5) 22.7 (2.9)
Lumbar spine BMD (g/cm2) 0.771 (0.104) 0.769 (0.107)
Serum calcium (mmol/L) 2.35 (0.09) 2.35 (0.09)
P1NP (μg/L) 50.5 (18.1) 52.2 (21.9)
s-CTx (ng/L) 542 (250) 581 (235)
25(OH)D (ng/mL) 19.8 (7.3) 19.4 (7.6)
25(OH)D (≤15 ng/mL), n (%) 29 (28.7) 34 (31.8)
ALN/D5600 combination tablet of alendronate 70 mg plus vitamin D3
5600 IU once weekly, BMD bone mineral density, BMI body mass index,
FAS full analysis set, s-CTx serum C-telopeptides of type 1 collagen, SD
standard deviation, N number of patients in FAS, P1NP procollagen type

























































































































































Fig. 2 Percent change from baseline in BMD at a the lumbar spine, b total hip, c femoral neck, d and trochanter, at months 6 and 12 (FAS). ALN/D5600
combination tablet of alendronate 70 mg plus vitamin D3 5600 IU once weekly, BMD bone mineral density, FAS full analysis set, SE standard error
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(95 % CI −81.4, −76.8), and for calcitriol were −16.8 % (95 %
CI −22.5, −10.5) and −27.2 % (95 % CI −34.6, −19.0), re-
spectively. Corresponding data at month 12 for ALN/D5600
were −68.1 % (95 % CI −70.8, −65.1) and −76.2 % (95 % CI
−78.6, −73.5), and for calcitriol were −17.0 % (95 % CI
−23.8, −9.6) and −24.2 % (95 % CI −31.6, −16.0), respective-
ly. Between-treatment differences were statistically significant
for P1NP and s-CTx at months 6 and 12.
Serum 25(OH)D
Figure 4 shows (a) changes from baseline in 25(OH)D, and
the distribution of 25(OH)D concentrations after treatment
with ALN/D5600 or calcitriol at month 6 (b) and month 12
(c) in the FAS. Mean 25(OH)D levels in the ALN/D5600
group increased from 19.7 ng/mL at baseline to 29.4 and
30.2 ng/mL at months 6 and 12, respectively. In the calcitriol
group, mean 25(OH)D levels decreased slightly from baseline
(19.4 ng/mL) to month 6 (16.1 ng/mL) but were similar to
baseline levels at month 12 (20.3 ng/mL). At month 6, the
proportion of patients with 25(OH)D defined thresholds
(<15 and <20 ng/mL) was significantly higher in the calcitriol
group (48.6 and 72.9 %, respectively) than in the ALN/D5600
group (1.0 and 5.9 %, respectively) (both, p<0.001). By
month 12, the proportion of patients with 25(OH)D below
the same thresholds (<15 and <20 ng/mL) had decreased in
the calcitriol group (25.5 and 47.1 %, respectively) and
remained very low in the ALN/D5600 group (1.0 and 4.1 %,
respectively) (both, p<0.001). Similar results were observed
in the PPS.
Safety and tolerability
Table 2 presents all AEs with an incidence >5 % in either
treatment group. All randomized patients who were adminis-
tered at least one dose of the study drug (N=215) were includ-
ed in the evaluation of safety (APaT population). The overall
safety profile appeared to be similar between groups. While
no statistical testing was conducted, small differences in AE
incidence were generally consistent with the recognized safety
profile of each treatment.
By the end of month 12, the numbers and proportion of
patients with at least one AEwere 64/107 (59.8%) and 74/108
(68.5 %) in the ALN/D5600 and calcitriol groups, respective-
ly. The number of patients with drug-related AEs was higher
in the ALN/D5600 group (14.0 %) than that in the calcitriol
group (7.4 %). The most frequently reported drug-related AE
in the ALN/D5600 group was upper abdominal pain (3.7 %).
The proportion of patients with at least one serious AE (SAE)
in the ALN/D5600 group (3.7 %) and in the calcitriol group
(4.6 %) was similar. None of the SAEs were considered to be









































































Fig. 3 Percent change from baseline in bone turnover markers: a P1NP
and b s-CTx (FAS). ALN/D5600 combination tablet of alendronate 70mg
plus vitamin D3 5600 IU once weekly, CI confidence interval, FAS full
analysis set, LS least squares, P1NP procollagen of type 1 N-terminal




































Fig. 4 Changes from baseline in serum 25(OH)D concentrations after
treatment with ALN/D5600 or calcitriol (FAS). ALN/D5600 combination
tablet of alendronate 70 mg plus vitamin D3 5600 IU once weekly, FAS
full analysis set, SE standard error, 25(OH)D 25-hydroxy vitamin D.
*Post hoc analysis: two-sample independent t test without adjustments
for covariates
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occurred in 7 (6.5 %) patients in the ALN/D5600 group and 3
(2.8 %) patients in the calcitriol group; these were assessed as
drug related in 3 (2.8 %; gastrointestinal disorders including
abdominal discomfort, gastritis, and esophageal pain which
were reported by 1 patient each) and 0 patients, respectively.
No deaths were reported. Fractures were reported by 1 patient
(0.9 %: patella fracture, SAE) in the ALN/D5600 group and
by 4 patients (3.7 %: 2 patients with femoral neck fractures,
both considered an SAE; 1 patient with a non-serious spinal
compression fracture and a non-serious foot fracture; 1 patient
with a spinal compression and a vertebral fracture, both con-
sidered an SAE) in the calcitriol group.
Differences in the incidence of hypercalcemia, hypercalci-
uria, or either of these two events between ALN/D5600 and
calcitriol groups at month 12 were not statistically significant
(Table 2, post hoc analysis). There was 1/108 (0.9 %) patient
in the calcitriol group who was defined as having hypercalce-
mia (serum non-corrected calcium >2.60 mmol/L) during the
study.
No clinically important findings were observed in labora-
tory values and vital signs, with no notable differences be-
tween the two treatment groups. There was a higher decrease
in total alkaline phosphatase over time with ALN/D5600 than
with calcitriol (decreases of -22.1 and -6.5 U/L, respectively,
by month 12). No laboratory abnormalities were reported as
drug-related SAEs or drug-related AEs that led to study drug
discontinuation.
Discussion
This study investigated the efficacy and safety of ALN/D5600
once weekly compared with those of calcitriol in Chinese
postmenopausal women. To our knowledge, this was the first
clinical study in China to compare the therapeutic profiles of a
fixed-dose combination of a bisphosphonate and vitamin D3
directly with calcitriol treatment in the clinical setting. In the
study, 215 patients received at least one dose of the study drug
and 89.5 % (196/219) of patients completed the 6-month ex-
tension period, indicating a good patient retention. Consistent
with the stated hypothesis and the primary efficacy end point
of the study, ALN/D5600 was superior to calcitriol as mea-
sured by percent change from baseline in lumbar spine BMD
at month 6, with a treatment difference of 2.0 % (p<0.001,
adjusted for baseline 25(OH)D level) in favor of ALN/D5600.
This difference was maintained at month 12, with a treatment
difference of 2.9 % (p<0.001). ALN/D5600 also increased
BMD at the total hip, the femoral neck, and the trochanter
more than calcitriol 0.25 μg daily after 12 months of treat-
ment. The within-group increases in BMD at both month 6
Table 2 AEs through month 12
with an incidence >5 % in either
treatment group, and AEs of
special interest (APaT)
ALN/D5600 (N=107) Calcitriol (N=108)
n (%) n (%)
AEs in >5 % of patients in either treatment group
Nasopharyngitis 10 (9.3) 12 (11.1)
Abdominal pain, upper 9 (8.4) 3 (2.8)
Urine calcium increased 8 (7.5) 12 (11.1)
Upper respiratory tract infection 7 (6.5) 6 (5.6)
Arthralgia 6 (5.6) 5 (4.6)
Diarrhea 4 (3.7) 6 (5.6)
Vitamin D deficiency 0 (0.0) 6 (5.6)
AEs of special interest—hypercalcemiaa and hypercalciuriab
One or more hypercalcemia or hypercalciuria 9 (8.4) 16 (14.8)
p=0.928
One or more hypercalcemia 0 (0.0) 1 (0.9)
p=0.840
One or more hypercalciuria 9 (8.4) 15 (13.9)
p=0.898
AE adverse event, ALN/D5600 combination tablet of alendronate 70 mg plus vitamin D3 5600 IU once weekly,
APaT all patients as treated, N number of patients as treated
a Hypercalcemia is defined as Bas per the investigator reported and/or serum calcium level >2.60 mmol/L in the
study by a laboratory assessment at any visit
b Hypercalciuria is defined as Bas per the investigator reported and/or 24-h urine calcium level >300mg/day in the
study by a laboratory assessment at any visit^
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and month 12 in the ALN/D5600 group are consistent with
the results of previous studies using alendronate 70 mg once
weekly or 10 mg daily doses of alendronate [10–16]. Treat-
ment with ALN/D5600 also resulted in significantly greater
reductions from baseline compared with that with calcitriol in
the bone turnover markers, P1NP and s-CTx, at both month 6
and month 12.
Although fracture risk reduction is the ultimate goal of
osteoporosis therapy, the present study was not sufficiently
powered to detect a statistically meaningful difference in ei-
ther vertebral or non-vertebral clinical fracture incidence be-
tween the two treatment groups. Rather, the study’s aimwas to
explore BMD changes and its related changes in biochemical
markers for the assessment of efficacy. In the entire study,
fractures were detected in 5 patients, 4 (3.7 %) in the calcitriol
group (2 [1.9 %] with vertebral fractures and 2 [1.9 %] with
femoral neck fractures), and 1 (0.9 %) in the ALN/D5600
group (patella fracture). Previous large studies have shown
that treatment with alendronate for 3 or 4 years significantly
increases BMD and reduces the risk of morphometric verte-
bral fractures in women with low BMD but no vertebral frac-
tures [17] and both hip and spine fractures in women with low
BMD and previous vertebral fracture [18]. In a subgroup of
patients without prior vertebral fractures with hip neck BMD
T-scores<–2.5, the risk of vertebral, hip, and a composite end
point of any clinical fracture were reduced in patients treated
with alendronate [17]. It is therefore reasonable to postulate
that treatment with ALN/D5600 would have a future clinical
benefit in reducing vertebral and non-vertebral fracture inci-
dence in Chinese postmenopausal women with osteoporosis.
There are no fracture studies on calcitriol 0.25 μg daily for
comparison; however, a 3-year study of 622 women with
postmenopausal osteoporosis and one or more vertebral com-
pression fractures showed that calcitriol 0.25 μg twice daily
significantly reduced the incidence of new vertebral fractures
compared with calcium [19].
In patients with osteoporosis, low 25(OH)D levels are
prevalent, regardless of geographic location [20]. In China
and most other countries, vitamin D supplementation, prefer-
ably 800 IU daily or above, and calcium are recommended for
use along with anti-resorptive therapies based on current
guidelines [4, 21, 22]. In this study population, the median
25(OH)D level at baseline was 18.5 ng/mL, which indicates
that more than 50 % of patients had a vitamin D level <20 ng/
mL. In addition, 30.3 % of patients had a vitamin D level
<15 ng/mL. As in previous studies [23, 24], ALN/D5600 ef-
fectively increased 25(OH)D levels: mean 25(OH)D increased
from 19.7 ng/mL at baseline to 29.4 ng/mL and 30.2 ng/mL at
months 6 and 12, respectively, and the proportion of patients
whose vitamin D levels were <15 and <20 ng/mL was 1.0 and
5.9 %, respectively, at month 6, and 1.0 and 4.1 %, respec-
tively, at month 12. Based on these data, ALN/D5600 is a
rational combination treatment option to help ensure that
patients receiving alendronate in China also have adequate
vitamin D.
In the calcitriol group, a decrease in mean 25(OH)D level
was observed at month 6 (from 19.4 to 16.1 ng/mL) with a
return to baseline (to 20.3 ng/mL) at month 12. One reason for
the initial decline might be that 1,25(OH)2D stimulates
25(OH)D catabolism. The body responds to 1,25(OH)2D by
enhancing expression of 25(OH)D-24-hydroxylase
(CYP24A1) to metabolize 25(OH)D and 1,25(OH)2D into
water-soluble inactive forms that are excreted in the bile
[25]. Additionally, efficient patient enrollment was seen in
the fall 2011, with the first 6 months of the study including
the winter period when lack of sun exposure could have led to
decreased 25(OH)D levels. Low 25(OH)D levels may not,
however, be important in patients who are being administered
calcitriol directly (taking into consideration calcitriol’s direct
effect on calcium absorption resulting in an effect on bone
turnover and lowering of PTH).
ALN/D5600 was generally well tolerated, and the safety
profile was consistent with that previously reported [23, 24]
and with the current product package insert. The incidence of
drug-related AEs was almost twice as high in the ALN/D5600
group compared with that in the calcitriol group (14.0 versus
7.4 %), with upper abdominal pain as the most common drug-
related AE reported among ALN/D5600-treated patients
(3.7 %). Discontinuations due to drug-related AEs were also
more common in the ALN/D5600 group (2.8 versus 0 %) and
were due to gastrointestinal disorders. This is consistent with
placebo-controlled trials of oral alendronate. Although infer-
ence testing did not show statistical significance (p not less
than 0.05), there was a slightly higher incidence of hypercal-
ciuria (events reported either as Bhypercalciuria^ or Burine
calcium increased^) with calcitriol than with ALN/D5600
(13.9 versus 8.4 % at month 12). In addition, there was only
one event of hypercalcemia reported, which was in the
calcitriol group.
A limitation of this study was the open-label design which
may have introduced bias. In addition, although BMD was
measured by either Hologic (Hologic Corporation) or GE Lu-
nar (GE Medical Systems) DXA machines and individual
sites followed quality control procedures recommended by
the manufacturers, there was no independent central BMD
quality control/quality assessment program. However, be-
cause the study was not large enough to compare fracture
incidence, central adjudication of events such as fractures
was not performed by either an internal or an external com-
mittee. Moreover, the study was not designed to distinguish
the relative contributions of ALN and vitamin D3 in reducing
bone loss and increasing BMD. In this study, parathyroid hor-
mone (PTH) levels were not measured over time, and thus, the
interaction between vitamin D and the anti-resorptive effect of
ALN could not be interpreted fully. A previous study showed
that while administration of vitamin D was not a requirement
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for ALN to decrease bone turnover in patients with sufficient
vitamin D, it did result in approximately 25% greater fall in s-
CTx in patients with vitamin D insufficiency (defined as
25(OH)D <20 ng/mL) [26]. The small within-group decreases
in bone turnover markers in the calcitriol group could have
been due to the start of either calcium supplements or calcitriol
(or the net effect of both). Other studies assessing the effects of
25(OH)D levels on BMD changes with ALN treatment indi-
cate that there is a minimum required 25(OH)D level for an
optimal effect of ALN. While BMD response may not vary
with baseline vitamin D levels when patients are supplement-
ed with vitamin D3, BMD response is correlated with
25(OH)D levels achieved by the end of treatment with com-
bined ALN and vitamin D [27–29].
In summary, ALN/D5600 showed significantly greater in-
creases in BMD at the lumbar spine and significantly greater
decreases in bone turnover markers compared with calcitriol
in Chinese postmenopausal women with osteoporosis. The
study did not evaluate whether the greater increase in BMD
resulted in fewer fractures. ALN/D5600 was also generally
well tolerated in Chinese patients with a safety profile consis-
tent with previous studies across various regions and races.
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